Overview

Irinotecan Plus Mitomycin in Treating Patients With Advanced Solid Tumors

Status:
Completed
Trial end date:
2001-05-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus mitomycin in treating patients who have advanced solid tumors that are persistent or recurrent.
Phase:
Phase 1
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborator:
National Cancer Institute (NCI)
Treatments:
Camptothecin
Irinotecan
Mitomycin
Mitomycins